Gene Security Network (GSN) has initiated enrollment for a prospective randomized trial in collaboration with Ferring Pharmaceuticals to evaluate the impact of GSN’s advanced preimplantation genetic diagnosis (PGD) with Parental Support on pregnancy and implantation rates in in vitro fertilization (IVF).
Impact of Parental Support on pregnancy Outcomes (IPSO) is a multicenter US trial designed to evaluate the potential of GSN’s PGD technology to increase IVF success.
The study subjects enrolled in the trial will be randomised to either a Test or Control arm and will have their embryos tested before transfer to the mother’s uterus to determine whether they are likely to have a normal number of chromosomes.
Gene Security Network CEO Matthew Rabinowitz said that the field of reproductive medicine needed a multicenter prospective randomised trial to formally evaluate the impact of newer and more comprehensive testing technologies, like Parental Support, on pregnancy rates.
“We are pleased that Ferring Pharmaceuticals is collaborating with us to bring this study to fruition. We hope and expect that the promising results we have seen previously will be replicated in this controlled trial,” Rabinowitz said.